Seventure Partners joins ViroVet in series B funding

Animal health company focused on combatting viral infections in livestock Leuven,

Belgium: 28 May 2020 — ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce that it has successfully concluded the first closing of its series B financing round, raising over 6 million euros. The financing will be used to further develop and launch its veterinary product portfolio. The investment round was led by Seventure Partners with participations from PMV, Biotech Fund Flanders, Capricorn Partners, Agri Investment Fund, KU Leuven, Gemma Frisius Fund and Vives II. ViroVet pioneers in developing novel and innovative vaccines based on a unique proprietary technology platform originating from the Rega Institute for Medical Research of KU Leuven. With this technology platform, vaccines can be designed and produced faster and more cost-effectively. The vaccines are tailor-made and are thermostable thereby removing any cold-chain requirement. The company also develops fast-acting antiviral drugs that are critical to the effective control and treatment of respiratory diseases of cattle and swine, thereby reducing secondary bacterial infections and the associated use of antibiotics. Following successful trials, the company has now entered full development of its BVD antiviral drug.

More info on ViroVet’s website.